Apollomics, Inc.
NASDAQ:APLMBiotechnology
+$6.03 today
- Market cap
- $52.00M
- Beta
- 1.45
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$25.98
Volume 0.02M
Average 0.02M
APLM Debt Repayment
Cash used to repay borrowings during the period.
Apollomics, Inc.NASDAQ: APLM
Debt Repayment · Q4 FY2025 · quarter ended Dec 2025
Debt repayment turns negative
Q4 FY2025 debt repayment was -$125K, compared with $0 a year earlier.
Context
- Debt repayment amounted to 43.9% of revenue in FY2025, down 289.9 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 3.73M USD
- Year-over-year change
- +464.9%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.73M | +464.9% |
| FY2024 | 2024-12-31 | 661K | -97.3% |
| FY2023 | 2023-12-31 | 24.04M | +4154.1% |
| FY2022 | 2022-12-31 | (593K) | -12.3% |
| FY2021 | 2021-12-31 | (528K) | — |
Debt Repayment vs competitors
How APLM compares with its peers on the latest reported figures
- APLM's FY2025 debt repayment of $3.73M is the largest of the 2 companies compared; the peer median is $0.
- Debt repayment amounts to 43.9% of revenue for APLM, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $3.73M | +464.9% | — | 43.9% | |
| LTM Jun 2024 | $0 | — | -32.3% | 0.0% | |
| Peer median (excluding APLM) | $0 | — | -32.3% | 0.0% | |
Competitors are the stored peer set for APLM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (94.8M) | (240.81M) | (172.59M) | (53.6M) | (10.94M) |
| Depreciation & Amortization | 681K | 775K | 669K | 361K | 255K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.12M | 3.58M | 12.69M | 10.93M | (979K) |
| Change in Working Capital | 2.64M | 6.49M | (3.57M) | 1.04M | (380K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 2.64M | 6.49M | (3.57M) | 1.04M | (380K) |
| Other Non-Cash Items | 40.04M | 187.14M | 119.6M | 12.53M | 1.67M |
| Operating Cash Flow | (43.31M) | (42.82M) | (43.21M) | (28.74M) | (10.37M) |
| Capital Expenditures | (7.55M) | (367K) | (6K) | (24K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (103.79M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 71.95M | 29M | 20.49M | 5.76M | 0 |
| Other Investing Activities | (7.06M) | 420K | 884K | 246K | 218K |
| Investing Cash Flow | (38.95M) | 29.05M | 21.37M | 5.98M | 218K |
| Debt Repayment | (528K) | (593K) | 24.04M | 661K | 3.73M |
| Common Stock Issued | 141K | 392K | 85K | 0 | 7K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.26M) | (93K) | (2.9M) | (193K) | (65K) |
| Financing Cash Flow | (1.64M) | (294K) | 21.23M | 468K | 3.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 2K | (15K) |
| Net Change in Cash | (83.91M) | (14.07M) | (619K) | (22.29M) | (6.49M) |
| Free Cash Flow | (50.86M) | (43.19M) | (43.22M) | (28.77M) | (10.37M) |
Apollomics, Inc.
NASDAQ:APLM
Intrinsic Alpha fair value
Locked
Current Price
$17.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.